Haemonetics heads into the week having done something rare — it left the analyst consensus behind.
The stock closed at $104.65 on August 18, up 20% on the week and 34% over the past month. The move was triggered by an August 6 earnings release that the Street largely didn't anticipate at current price levels. The mean analyst price target, at $104.10, now sits fractionally below where the stock is already trading. That gap — where the market has run ahead of the covering analysts — is the central tension this week.
The Street is scrambling to reset. Barrington Research lifted its target to $118 and maintained its Outperform rating. BTIG raised to $110, also holding Buy. Those are the bulls acknowledging reality. The more cautious voices at JP Morgan and Citigroup both raised targets post-earnings — JP Morgan moved from $62 to $86, Citigroup from $79 to $92 — but both held Neutral ratings. That divergence between the bull camp (believing the re-rating has room to run) and the neutral camp (marking targets to market without conviction) defines where the debate sits right now. The bull case rests on plasma segment momentum and recent FDA approvals; bears point to guidance that has come in below midpoint estimates, rising operating spend, and tariff exposure that clouds the FY2027 revenue picture. Forward EPS momentum ranks in the 81st percentile versus sector peers, which gives the bulls something concrete to lean on.
Short interest is a modest but building subplot. At 5.9% of the free float, it isn't extreme, but the week saw a 10.8% increase in shares short — a meaningful jump as some traders positioned against the rally. The borrow market, however, offers no ammunition for a squeeze narrative. Availability is extremely loose at 6,398%, meaning roughly 64 shares remain available to borrow for every one already lent out. Cost to borrow has fallen 30% over both the week and the month, now running at just 0.36%. Shorts face no friction entering or holding positions. The 52-week peak availability of 11.1% utilization tells the same story — this has never been a crowded or expensive short.
Options positioning has shifted in a direction worth noting. The put/call ratio climbed to 0.32, roughly one standard deviation above its 20-day average of 0.24. That's a mild but real pickup in hedging demand, consistent with investors locking in gains on a stock that has just moved 34% in a month. It doesn't read as outright fear — the ratio remains far below its 52-week high of 0.52 — but the turn higher from the 0.16 range that prevailed through July is a change worth tracking.
The most recent earnings reaction backs up the pattern. The August 6 print drove a 5.1% gain on the day and an 8.1% gain over the following five sessions — a clean beat-and-rally setup that explains why short positions built in the aftermath. Institutional holders show a broadly constructive posture: Neuberger Berman added 618,000 shares as of July 31, UBS Asset Management added 465,000, and Dimensional Fund Advisors added 259,000. The one notable trim came from Arrowstreet, which cut its position by 228,000 shares through June.
What to watch is whether the analyst consensus catches up with the price — specifically whether the neutral-rated firms at JP Morgan and Citigroup upgrade their stance, or whether the stock stalls as it runs above the current mean target of $104 with no next earnings date yet anchoring the calendar.
See the live data behind this article on ORTEX.
Open HAE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
